Alghaith, TaghredAlmoteiry, KhalidAlamri, AdwaAlluhidan, MohammedAlharf, AdelAl-Hammad, BanderAliafali, IbrahimSeiter, AndreasPisani, ElizabethHerbst, Christopher H.El-Saharty, SamehAlazemi, Nahar2021-06-282021-06-282020https://hdl.handle.net/10986/35846This document presents the major issues that were discussed in the process of working towards the development of a new medicines policy in Saudi Arabia, examining current national practice in light of international practices and experiences. The document is designed to foster discussion and help inform the development of a new national medicine policy. A detailed accounting of the evidence informing policy choices to be highlighted in an updated medicine policy are presented in Part I of this discussion paper; a proposed new National Medicine Policy itself is presented in Part ll. A new Medicine policy, once finalized and approved, will need to be implemented in a highly dynamic environment and must therefore allow for flexibility. It will need to be followed by the implementation of regulations, closely monitored, and adapted as necessary over time.CC BY 3.0 IGOPHARMACEUTICAL SYSTEMMEDICINE POLICYACCESS TO HEALTH CAREMEDICINE PRICINGPHARMACEUTICAL INDUSTRYWorking PaperWorld Bank10.1596/35846